NasdaqGM:PTGX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology.


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has Protagonist Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PTGX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-4.0%

PTGX

0.7%

US Biotechs

1.8%

US Market


1 Year Return

43.2%

PTGX

22.1%

US Biotechs

3.7%

US Market

Return vs Industry: PTGX exceeded the US Biotechs industry which returned 22.1% over the past year.

Return vs Market: PTGX exceeded the US Market which returned 3.7% over the past year.


Shareholder returns

PTGXIndustryMarket
7 Day-4.0%0.7%1.8%
30 Day143.3%4.9%5.6%
90 Day85.0%10.7%-7.4%
1 Year43.2%43.2%23.3%22.1%6.1%3.7%
3 Year92.7%92.7%36.3%31.7%28.3%19.8%
5 Yearn/a-2.5%-8.3%52.4%35.1%

Price Volatility Vs. Market

How volatile is Protagonist Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Protagonist Therapeutics undervalued compared to its fair value and its price relative to the market?

6.93x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PTGX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PTGX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PTGX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: PTGX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PTGX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PTGX is overvalued based on its PB Ratio (6.9x) compared to the US Biotechs industry average (3.8x).


Next Steps

Future Growth

How is Protagonist Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

2.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PTGX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PTGX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PTGX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PTGX's revenue (76% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: PTGX's revenue (76% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PTGX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Protagonist Therapeutics performed over the past 5 years?

-27.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PTGX is currently unprofitable.

Growing Profit Margin: PTGX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PTGX is unprofitable, and losses have increased over the past 5 years at a rate of -27% per year.

Accelerating Growth: Unable to compare PTGX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PTGX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: PTGX has a negative Return on Equity (-132.71%), as it is currently unprofitable.


Next Steps

Financial Health

How is Protagonist Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: PTGX's short term assets ($126.0M) exceed its short term liabilities ($36.4M).

Long Term Liabilities: PTGX's short term assets ($126.0M) exceed its long term liabilities ($35.9M).


Debt to Equity History and Analysis

Debt Level: PTGX's debt to equity ratio (15.7%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if PTGX's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PTGX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PTGX has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 22.9% each year.


Next Steps

Dividend

What is Protagonist Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PTGX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PTGX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PTGX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PTGX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PTGX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Dinesh Patel (62yo)

11.42yrs

Tenure

US$1,948,344

Compensation

Dr. Dinesh V. Patel, Ph.D., has been the Chief Executive Officer and President at Protagonist Therapeutics, Inc. since December 2008 and was its Interim Chief Financial Officer till May 28, 2019. Dr. Patel ...


CEO Compensation Analysis

Compensation vs Market: Dinesh's total compensation ($USD1.95M) is about average for companies of similar size in the US market ($USD2.29M).

Compensation vs Earnings: Dinesh's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Dinesh Patel
CEO, President11.42yrsUS$1.95m1.17% $6.4m
David Liu
Chief Scientific Officer and Head of Research & Development7yrsUS$1.20m0.11% $577.0k
Suneel Gupta
Chief Development Officer1.33yrsUS$1.33m0.15% $812.9k
Richard Shames
Clinical Advisor4.75yrsUS$1.26m0.018% $97.4k
Donald Kalkofen
Chief Financial Officer1yrno data0.0034% $18.6k
Samuel Saks
Chief Medical Officer2yrsno datano data
Tracy Woody
Executive Vice President of Commercial Development0.33yrno datano data

2.0yrs

Average Tenure

61yo

Average Age

Experienced Management: PTGX's management team is considered experienced (2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Dinesh Patel
CEO, President11.42yrsUS$1.95m1.17% $6.4m
Chaitan Khosla
Independent Director & Chairman of Scientific Advisory Boardno dataUS$153.69kno data
Harold Selick
Independent Chairmanno dataUS$162.59k0.044% $242.5k
William Waddill
Independent Director3.83yrsUS$138.84kno data
Charles Craik
Scientific Advisorno datano datano data
Mark Gallop
Scientific Advisorno datano datano data
Wayne Lencer
Clinical Advisorno datano datano data
Aida Habtezion
Clinical Advisorno datano datano data
Ellen Scherl
Clinical Advisorno datano datano data
Bryan Giraudo
Independent Director2yrsUS$129.03k0.052% $285.1k

3.8yrs

Average Tenure

59yo

Average Age

Experienced Board: PTGX's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PTGX insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 47.2%.


Top Shareholders

Company Information

Protagonist Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Protagonist Therapeutics, Inc.
  • Ticker: PTGX
  • Exchange: NasdaqGM
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$545.446m
  • Shares outstanding: 34.43m
  • Website: https://www.protagonist-inc.com

Number of Employees


Location

  • Protagonist Therapeutics, Inc.
  • 7707 Gateway Boulevard
  • Suite 140
  • Newark
  • California
  • 94560
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PTGXNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDAug 2016
PGFBST (Boerse-Stuttgart)YesCommon StockDEEURAug 2016

Biography

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat patients with moderate-to-severe Crohn’s disease; and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating inflammatory bowel disease. It is also involved in researching oral and injectable peptide-based product candidates for a range of conditions, including gastrointestinal diseases. The company has a license and collaboration agreement with Janssen Biotech, Inc. for the development, manufacture, and commercialization of PTG-200 for the treatment of Crohn’s disease and ulcerative colitis. Protagonist Therapeutics, Inc. was founded in 2006 and is headquartered in Newark, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/25 04:57
End of Day Share Price2020/05/22 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.